Featured Our Research
June 5, 2015
Chefs often cite their travels, mentors, or childhood dishes as points of inspiration for their work. But when it came to partnering with an organization doing good, New York chef Floyd Cardoz found inspiration in his family, most prevalently his father and his eldest son, Peter. “Peter was very bullied as […]
May 20, 2014
After a dozen years of searching, Analisa DiFeo, PhD, and her team have discovered what appears to be one of the key drivers in the spread of ovarian cancer. The culprit is a biomarker, which can signal the presence of a disease. In this instance, however, the biomarker known as […]
November 12, 2013
BioMotiv, a drug development accelerator based in Cleveland, and the Icahn School of Medicine at Mount Sinai, based in New York, are announcing the formation of Dual Therapeutics, a company focused on producing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Dual Therapeutics is based on intellectual property […]
November 6, 2013
A $250 million drug discovery initiative launched last year at University Hospitals of Cleveland has produced its second startup, this one based on cancer research from the Icahn School of Medicine at Mount Sinai. Dual Therapeutics will develop new treatments for prostate cancer, lung cancer and acute lymphoblastic leukemia, according to an […]
June 9, 2013
The Mary Kay Foundation 2013 Cancer Grant Recipients YSF Board Member Analisa DiFeo, Ph.D., Case Western Reserve University, Cleveland, OH Title of Project: Single Agent Dual Inhibition of the AKT and ERK Signaling Pathway for the Treatment of Ovarian Cancer David K. Ann, Ph.D., City of Hope, Los Angeles, CA […]
May 18, 2013
Crain’s is proud to honor these dedicated heroes for their achievements and outstanding level of care that enriches everyday life. Awards Luncheon: Tuesday, May 21 • 1:00am-1:30pm 2013 Health Care Heroes Award Recipients Administrator of the Year • Nursing: Catherine Koppelman, Chief Nursing Officer; University Hospitals • Hospital: Cynthia Moore-Hardy, […]
May 18, 2013
Dr. Goutham Narla and his team have found that by using a combination of two FDA approved drugs – Erlotinib and Trifluoperazine – a process that is causing lung tumor cells to die can be initiated. A team of researchers led by Dr. Goutham Narla at Case Western Reserve University […]
January 29, 2013
CLEVELAND, Ohio — Last spring, University Hospitals Case Medical Center and Case Western Reserve University recruited a physician-scientist whose key discoveries — made while in medical school — of a gene that suppresses cancerous tumors first put him on the scientific map more than a dozen years ago. A […]
October 1, 2012
July 18, 2012 Les Coleman was a non-smoker and led an active life fact of life. He was also a lifelong researcher so when the opportunity to join a clinical trial at Seideman Cancer Center at University Hospitals Case Medical Center arose, he jumped on it. We thought that he […]
October 1, 2012
University Hospitals Harrington Discovery Institute’s first Harrington Distinguished Scholar (Early Career Award) is Goutham Narla, MD, PhD, an Assistant Professor in the Department of Medicine and the Institute for Transformative Molecular Medicine, and a leading physician-scientist recruited from the Mount Sinai School of Medicine in New York. His laboratory focuses […]